Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
16 February 2018Website:
http://www.biotricity.comNext earnings report:
02 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:29:29 GMTDividend
Analysts recommendations
Institutional Ownership
BTCY Latest News
FY24 revenue up 25.2% YOY FY24 margins improved 1280 basis points to 69.3%, from 56.5% in the prior year; Q4-FY24 margins improved to 71.5%; margin expansion forecasted to continue FY24 operating expenses lower by 17.6% YOY Negative EBITDA reduced by $7.2 million - an improvement of 44.6% -- accelerating the Company's path to breakeven and EBITDA positive REDWOOD CITY, CA / ACCESSWIRE / June 27, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "Fiscal 2024 has been a year of massive transformation for Biotricity.
Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is excited to provide guidance for its upcoming Year-End Results. Biotricity announces expectations to meet analyst revenue target, while beating margin and loss targets.
REDWOOD CITY, CA / ACCESSWIRE / June 4, 2024 / Biotricity Inc.] (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is thrilled to announce that the majority of its existing Preferred A shareholders have converted 97% of all the preferred A shares into Restricted Common Stock, increasing their support and commitment to the Company. "This recent conversion shows the growing enthusiasm our long-term shareholders have for the Company and their confidence in the execution and upcoming milestones of the company," remarked Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.
After losing some value lately, a hammer chart pattern has been formed for Biotricity (BTCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Biotricity Inc. (BTCY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Biotricity Inc. (BTCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotricity Inc. (BTCY) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.54 per share a year ago.
Biotricity, Inc. (NASDAQ:BTCY ) Q2 2024 Earnings Conference Call November 14, 2023 6:00 PM ET Company Participants Debra Chen - IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Davin - H.C. Wainwright Operator Good afternoon, and welcome to Biotricity's Second Quarter Fiscal 2024 Financial Results and Business Update Conference Call.
Biotricity (NASDAQ:BTCY ) Q1 2024 Earnings Conference Call August 15, 2023 4:30 PM ET Company Participants Debra Chen – Investor Relations Waqaas Al-Siddiq – Founder and Chief Executive Officer John Ayanoglou – Chief Financial Officer Conference Call Participants Kevin Dede – H.C. Wainwright Operator Good afternoon, and welcome to Biotricity's First Quarter Fiscal 2024 Financial Results and Business Update Conference Call.
What type of business is Biotricity?
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
What sector is Biotricity in?
Biotricity is in the Healthcare sector
What industry is Biotricity in?
Biotricity is in the Medical Devices industry
What country is Biotricity from?
Biotricity is headquartered in United States
When did Biotricity go public?
Biotricity initial public offering (IPO) was on 16 February 2018
What is Biotricity website?
https://www.biotricity.com
Is Biotricity in the S&P 500?
No, Biotricity is not included in the S&P 500 index
Is Biotricity in the NASDAQ 100?
No, Biotricity is not included in the NASDAQ 100 index
Is Biotricity in the Dow Jones?
No, Biotricity is not included in the Dow Jones index
When does Biotricity report earnings?
The next expected earnings date for Biotricity is 02 July 2024